319 results on '"Winton, Elliott F."'
Search Results
2. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
3. Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera
4. Phase 2 study of add-on parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib: Final results
5. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
6. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
7. Ruxolitinib for the treatment of patients with polycythemia vera
8. Predicting early blast transformation in chronic-phase chronic myeloid leukemia: Is immunophenotyping the missing link?
9. The p75 Peptide is the Receptor for Interleukin 2 Expressed on Large Granular Lymphocytes and is Responsible for the Interleukin 2 Activation of These Cells
10. Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia
11. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies
12. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
13. Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase
14. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
15. Myelofibrosis Management After Ruxolitinib Failure
16. Long-term Treatment With Rituximab of Autoimmune Autonomic Ganglionopathy in a Patient With Lymphoma
17. Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study
18. Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors
19. Update in acute leukemia 2003: A risk adapted approach to acute myeloblastic leukemia in adults
20. Update on myelodysplastic syndromes: New approaches to classification and therapy
21. Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings
22. Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib
23. Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
24. Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
25. Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial
26. Treatment of Residual Disease in AML: Interim Analysis of a Southeastern Cancer Study Group Prospective Randomized Clinical Trial
27. The Natural Immune System and Hematocytopenias
28. STUDIES RELATING TO WATER MINERALIZATION AND HEALTH
29. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
30. Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).
31. Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF).
32. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia
33. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
34. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia
35. Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study
36. A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States
37. Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial
38. A Prospective Multi-Center Trial Shows Reduction of Early Deaths (ED) and Improved Survival in Elderly Acute Promyelocytic Leukemia (APL) Patients (>60 years). Results of Using a Simplified Treatment Algorithm and Expert Support in Georgia, South Carolina and Neighboring States
39. Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia
40. Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions
41. Costs associated with induction chemotherapy in adult acute myeloid leukemia (AML) managed in a tertiary care specialized unit.
42. Profile of cell cycle in hemopoietic malignancy by DNA/RNA quantitation using 7AAD/PY
43. Simultaneous three-color analysis of the surface phenotype and DNA-RNA quantitation using 7-Amino-actinomycin-D and Pyronim Y
44. Poor Outcomes with Hyper CVAD Induction for T-Cell Lymphoblastic Leukemia/Lymphoma
45. Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Who Switch to Imatinib Following Optimal Response to Second Generation Tyrosine Kinase Inhibitors
46. Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience
47. Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)
48. Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma
49. Phase III randomized, double-blind, active-controlled study of momelotinib versus ruxolitinib in patients with myelofibrosis.
50. Improving Outcomes in Elderly Acute Promyelocytic Leukemia Patients in the Real World: A Personalized Treatment Approach Along with Expert Support Might Reduce Early Deaths
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.